Aspira Pathlab & Diagnostics Ltd (ASPIRA) is currently trading at 101.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Aspira Pathlab & Diagnostics Limited (ASDL) is a leading pathology specialist in India, offering a wide range of diagnostic services. The company operates with an asset-light model but faces high operational costs which it is working to optimize. Aspira has a strong presence in Maharashtra and aims to strengthen its regional footholds before scaling operations. The company is adopting new technologies like chatbots and patient engagement platforms to enhance customer experience.

Over the past 52 weeks, Aspira Pathlab & Diagnostics Ltd has traded between a low of ₹49.00 and a high of ₹135.88. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Aspira Pathlab & Diagnostics Ltd has a market capitalization of approximately 103.65. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Aspira Pathlab & Diagnostics Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 43.19 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 103.65 Cr, Aspira Pathlab & Diagnostics Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Aspira Pathlab & Diagnostics Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Aspira Pathlab & Diagnostics Ltd is 43.19. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.